Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07050173 · ClinicalTrials.gov registry record · Phase 1
Monitoring Patients With Repetitive Head Impact With Gamma-glutamylcysteine Supplementation
A Phase 1 study of Repetitive Head Impacts, sponsored by Pravat Mandal.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07050173: Recruiting Phase 1 study of Repetitive Head Impacts, sponsored by Pravat Mandal.
NCT07050173 is a Phase 1 study of Repetitive Head Impacts that is actively recruiting participants, run by Pravat Mandal. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07050173, a Phase 1 study of Repetitive Head Impacts, is actively recruiting participants, sponsored by Pravat Mandal.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to test whether the gamma - glutamylcystiene (GGC) oral supplement can reach the brain and subsequently increase antioxidant glutathione (GSH) level in people with repetitive head impact (RHI). This will reduce the oxidative stress related injury in people with RHI.This unique study's main objective is to test the: 1. Change in GSH in brain and blood levels through GGC supplementation. 2. Change in the cognitive function in RHI patients due to GGC supplementation.
Primary Outcome
(MRS) is a non-invasive imaging technique, to detect various neurochemical (e.g. glutathione) using MEGA-PRESS sequence from 1H MR spectroscopy.
Conditions Studied
Interventions
- DRUG Gamma-glutamylcysteine (GGC)
Study Locations (1)
Pennsylvania
- UPMC Presbyterian Hospital - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-03-20 |
| Est. Completion | 2027-12-27 |
| Phase | Phase 1 |
What NCT07050173 shows while recruiting
NCT07050173 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Repetitive Head Impacts appearing as the primary indexed condition, and to 1 intervention - of which Gamma-glutamylcysteine (GGC) is the first listed.
NCT07050173 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07050173 about?
NCT07050173 is a clinical study titled "Monitoring Patients With Repetitive Head Impact With Gamma-glutamylcysteine Supplementation". The goal of this clinical trial is to test whether the gamma - glutamylcystiene (GGC) oral supplement can reach the brain and subsequently increase antioxidant glutathione (GSH) level in people with repetitive head impact (RHI). This will reduce the oxidative stress related injury in people with RHI...
What is the current status of trial NCT07050173?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2026-03-20. Estimated completion is 2027-12-27.
What conditions does trial NCT07050173 study?
This clinical trial studies the following conditions: Repetitive Head Impacts.
What interventions are being tested in trial NCT07050173?
The interventions under investigation include: Gamma-glutamylcysteine (GGC) (DRUG).
Who is sponsoring clinical trial NCT07050173?
This trial is sponsored by Pravat Mandal, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07050173 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Repetitive Head Impacts
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07050173's enrollment target sits among peer trials
30 1333rd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI